ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2. Planned surveillance period 5 years and 6 months
Epistemonikos ID: eea6dfc8f1b6e0d6bd17ebdb84a3cd913d5a98bc
First added on: May 21, 2024